Kornimate/medical-research-clean huggingface dataset:
comparison of ultrasonographic and clinical features of different energy levels extracorporeal shock wave therapy in plantar fasciitis

Conditions: Extracorporeal Shock Wave Therapy

Summary: plantar fasciitis is the most common cause of heel pain in adults. it received fda approval in 2000 for eswt in the treatment of plantar fasciitis in adults whose pain did not resolve with conservative treatment. eswt energy levels are categorized as high, medium and low. it is not yet clear which energy level is most effective in the clinical recovery and pain relief of plantar fasciitis after eswt treatment. although there are studies in the literature evaluating the effect of different energy densities in the treatment of plantar fasciitis with eswt, there are very few studies comparing different treatment doses of eswt. the aim of this study was to evaluate and compare the therapeutic effects of low, medium and high energy eswt in patients with plantar fasciitis, and also to examine the correlation between plantar fascia thickness changes ultrasonographically and clinical outcomes.


Eligibility criteria:
inclusion criteria: presence of heel pain, tenderness at the insertion site of the plantar fascia on the anteromedial aspect of the calcaneal tubercle elicited by palpation, and unresponsiveness to medical treatment. exclusion criteria: history of inflammatory rheumatic disease, trauma of the foot or foot surgery, local dermatological lesion or infection, impaired peripheral circulation, a neurological disorder such as radiculopathy and neuropathy, patients with sequelae of lower extremity fracture, a congenital or acquired deformity, malignancy, cardiac pacemaker, metal implant at the application site, pregnancy, anticoagulant use for coagulopathy

Keywords: extracorporeal shock wave therapy ultrasonography plantar fasiit
inhaled amikacin treatment for nontuberculous mycobacterial lung disease

Conditions: Pulmonary Non-tuberculous Mycobacterial Lung Disease

Summary: the incidence of chronic pulmonary disease caused by nontuberculous mycobacteria (ntm) in human immunodeficiency virus (hiv)-negative patients has been increasing worldwide. in korea, the common etiologic pathogens for this disease are mycobacterium avium complex (mac) and mycobacterium abscessus. treating ntm lung diseases can be extremely difficult and may require multiple drugs. amikacin is an effective antibiotic for ntm infection. however, intravenous amikacin treatment is limited by its systemic route of administration and a lot of adverse events. amikacin inhalation treatment could overcome these limitations and also could be effective for treatment of ntm pulmonary disease due to maintaining a high lung concentration. the purpose of this study is to determine whether amikacin inhalation treatment is effective in patients with mac infection who experienced treatment failure after standard treatment for more than 6 months or with m. abscessus infection.


Eligibility criteria:
inclusion criteria: 1. diagnosis of ntm lung lung disease in accordance with the 2007 ats/idsa criteria. 2. mac lung disease with persistent sputum culture positive after 6 months of standard treatment 3. m. abscessus lung disease with persistent sputum culture positive after 6 months of standard treatment 4. new case of m. abscessus pulmonary disease after completion of initial 4 weeks intravenous antibiotics treatment exclusion criteria: 1. subjects with negative sputum culture before starting of this study 2. forced expiratory volume in 1 second (fev1) \<30% of predicted at screening. 3. positive in hiv test. 4. subjects with chronic renal insufficient state (serum creatinine level is more than 2.0 mg/dl) 5. subjects with decreased liver function (serum total bilirubin level is more than 2 mg/dl or ast or alt are more than 1.5 times of upper normal limits) 6. active any malignancy requiring chemotherapy or radiation therapy within one year prior to screening. 7. subjects with history of allergy to amikacin. 8. subjects with pregnant state or women of childbearing age with no appropriate contraception.

Keywords: lung diseases anti-infective agents therapeutic uses amikacin
a prospective, observational study utilizing phasix™ mesh during ventral and incisional hernia repair surgery

Conditions: Ventral Hernia

Summary: the objective of this study is to collect efficacy, safety and utility data with phasix™ mesh in ventral and incisional repair procedures by evaluating the following: 1. hernia recurrence rate of ventral and incisional hernias post repair with phasix™ mesh for up to 12 months post surgery. 2. perioperative, short-term and long-term procedural and/or device related complications. 3. abdominal wall function and mobility.


Eligibility criteria:
inclusion criteria: the subject must meet all of the relevant criteria listed below to be enrolled in the study: 1. subject must be ≥18 years of age. 2. subject or subject's legally authorized representative must be willing give written informed consent. 3. subject must be diagnosed with a ventral, incisional or first-recurrent incisional hernia. 4. hernia size greater than 10cm2 and less than 250cm2 5. subject must be willing to undergo ventral hernia repair and be able to undergo all other study procedures as outlined in this protocol. exclusion criteria: the subject must be excluded from study enrollment if any of the following criteria are met: 1. subject's hernia is multiply recurrent. 2. cdc wound classification other than clean or clean-contaminated 3. the use of surgical repair as a bridge. 4. patient has a contraindication to placement of mesh. 5. concomitant procedures with wound classification other than clean 6. subject has peritonitis. 7. subject is on or suspected to be placed on chemotherapy medications during any part of the study. 8. subject's body mass index (bmi) \>55 kg/m2. 9. subject has cirrhosis, and/or ascites. 10. subject is american society of anesthesiology class 4 or 5. 11. subject is known to be infected with human immunodeficiency virus (hiv). 12. subject has known allergies to tetracycline or kanamycin. 13. subject has a life expectancy of less than 2 years at the time of enrollment. 14. subject has any condition in the opinion of the investigator that would preclude the use of the study device, or preclude the subject from completing the follow-up requirements.

Keywords: resorbable mesh phasix mesh
randomized, placebo controlled study of the efficacy and safety of pf-02545920 in subjects with huntington's disease

Conditions: Huntington's Disease

Summary: this study is a 26 week, randomized, parallel group, double blind comparison of pf-02545920 5 mg, pf-02545920 20 mg, and placebo dosed bid in the treatment of motor impairment of subjects with huntington's disease. a total of approximately 260 subjects are planned to be randomized in the study. primary endpoint is the change from baseline in the total motor score (tms) assessment of the unified huntington disease rating scale (uhdrs) after 26 weeks of treatment. secondary endpoints will include change from baseline in the total maximum chorea (tmc) score of the uhdrs after 13 and 26 weeks of treatment and clinical global impression-improvement score after 13 and 26 weeks of treatment.


Eligibility criteria:
inclusion criteria: * cag repeat equal or greater than 36; * total motor score equal or greater than 10; * total functional capacity equal or greater than 7. exclusion criteria: * clinically significant neurologic disorder other than huntington's disease; * other severe acute psychiatric conditions, mania and/or psychosis; * history of neutropenia, and myeloproliferative disorders;

Keywords: huntington; chorea; total motor score; cag repeat: total functional capacity; motor cognitive and behavioral symptoms
intrathecal dual checkpoint inhibitor (pd-1 and ctla-4) in combination with pemetrexed for leptomeningeal metastasis

Conditions: Leptomeningeal Metastasis; Pemetrexed; PD-1 Inhibitor; CTLA4; Solid Tumors

Summary: this phase i/ii study is to evaluate the recommended dose, safety, feasibility, and therapeutic response of intrathecal dual checkpoint inhibitor (targeting pd-1 and ctla-4 with ql1706) in combination with pemetrexed in patients with leptomeningeal metastasis.

this study is a prospective, single-arm, phase i/ii clinical trial evaluating intrathecal dual checkpoint inhibitor (targeting pd-1 and ctla-4 with the bispecific antibody ql1706) in combination with pemetrexed for the treatment of leptomeningeal metastasis. intrathecal pemetrexed is administered twice weekly for 2 weeks (induction phase), then weekly for 4 weeks (consolidation phase), and monthly thereafter (maintenance phase). intrathecal ql1706 (a pd-1/ctla-4 bispecific antibody) is given every two weeks during the six-week induction phase, followed by monthly injections in the maintenance phase, until disease progression or death. the primary objectives are to determine the recommended dose of intrathecal ql1706 in combination with pemetrexed and to assess safety based on the incidence of treatment-related adverse events. clinical response rate, progression-free survival related to leptomeningeal metastasis, and overall survival are also evaluated. patients undergo cerebrospinal fluid and blood specimen collection to evaluate potential clinical, molecular, and/or immune predictors of treatment efficacy and safety.

Eligibility criteria:
inclusion criteria: 1. histologically or cytologically confirmed diagnosis of solid tumors; cerebrospinal fluid cytopathology is positive. 2. male or female aged between 21 and 75 years; normal liver and kidney function; wbc≥4000/mm3, plt≥100000/mm3. 3. no history of severe nervous system disease; no severe dyscrasia. exclusion criteria: 1. any evidence of nervous system failure, including severe encephalopathy, grade 3 or 4 leukoencephalopathy on imaging, and glasgow coma score less than 11. 2. any evidence of extensive and lethal progressive systemic diseases without effective treatment. 3. a history of hiv or aids, acute or chronic hepatitis b or c infection, previous anti-pd1 therapy-induced pneumonitis, or have ongoing \>grade 2 adverse events of such therapy; or ongoing autoimmune disease that required systemic treatment in the past 2 years. 4. patients with poor compliance or other reasons that were unsuitable for this study.

Keywords: leptomeningeal metastasis dual checkpoint inhibitor pemetrexed
two topical k40 formulations in adults with seborrhoeic dermatitis (sd) of the scalp

Conditions: Seborrhoeic Dermatitis of the Scalp

Summary: seborrhoeic dermatitis (sd) is a papulosquamous (presence of both papules and scales) disorder patterned on the sebum-rich areas of the scalp, face, and trunk. the current treatment does not cure the disease permanently. therefore it must be repeated when the symptoms recur, or even prophylactically. corticosteroids and antifungals are the mainstay of therapy. topical corticosteroids rapidly reduce the cutaneous signs of disease, but are associated with a high frequency of relapse when treatment is stopped. they are reserved for acute flare-ups only as they may precipitate recurrences and dependence. in addition, chronic use of corticosteroids is associated with side-effects. the scientific rationale for the use of k40 for treatment of sd was based on clinical evidence that k40 improves erythema and desquamation with mild adverse reactions in a few cases. the primary objective of the study was to evaluate the efficacy of k40 (k40a and k40b combined) compared to placebo after 4 weeks treatment as measured by the sum of erythema and desquamation scores at week 4.


Eligibility criteria:
inclusion criteria: * male or female (including fertile women) * 18-65 years of age * seborrhoeic dermatitis of the scalp for at least 2 months * presenting erythema and desquamation of mild, moderate, pronounced or severe intensity * signed written informed consent exclusion criteria: * patient on an antifungal, selenium sulphite or corticosteroid therapy within the last 2 weeks prior to start of study treatment * any other cutaneous disease of the face requiring a specific topical treatment (corticosteroids, antifungals, antibiotics, retinoids, benzoyl peroxide or a-hydroxyacids) during the previous 15 days * oral treatment with cyclines, lithium, antifungals or inhaled corticosteroids during the previous month * use of systemic corticosteroids and retinoids during the previous 2 months * sd associated with parkinson's disease, human immunodeficiency virus infection * current or any history of ear, nose and throat carcinoma, * current or any history of severe concomitant disease according to investigator'sjudgement * allergy to any of the tested treatment components

Keywords: seborrhoeic dermatitis scalp k40a k40b
investigating the impact of duration and amount of light on the circadian system response - aim 3

Conditions: Alzheimer's Disease; Mild Cognitive Impairment

Summary: investigate the long-term impact of amount and duration of tailored lighting intervention (tli) obtained from aims 1 and 2 on sleep, cognition, circadian marker, mood, and behavior in ad/adrd patients. for this single-arm, randomized, placebo-controlled study, the researchers plan to recruit 100 participants who will experience either the active tli or the placebo for 6 months.


Eligibility criteria:
inclusion criteria: * diagnosis of alzheimer's disease or related dementia with a montreal cognitive assessment score \<25 * sleep disturbance with a pittsburgh sleep quality index score ≥5 exclusion criteria: * extensive brain vascular disease, traumatic brain injury, multiple sclerosis, parkinson's disease * obstructing cataracts * severe macular degeneration * use of sleep medication * use of oral melatonin * untreated moderate to severe sleep apnea * severe restless leg syndrome - blindness
reflectance confocal microscopy of wounds during moh's surgery: feasibility testing of a mosaicing algorithm for intraoperative imaging of cancer margins

Conditions: Basal Cell Carcinoma; Squamous Cell Carcinoma

Summary: the purpose of this study is to evaluate a new instrument that shines light and takes digital pictures of skin. the goal is to develop a technique that may enable fast and accurate assessment of surgical margins in the excision of basal cell carcinoma (bcc) or squamous cell carcinoma (scc). the investigators will evaluate the pictures obtained by the confocal microscope to determine whether this technique may be useful in the future for helping mohs surgeons remove cancers. in the future, patients may benefit with shorter surgery and improved care.


Eligibility criteria:
inclusion criteria: * patients undergoing mohs surgery for basal cell carcinoma (bcc )or squamous cell carcinoma (scc). . * ability to sign informed consent. * age ≥ 18 years. exclusion criteria: * mohs surgery located on a site that may not be convenient to confocal imaging. * inability to give informed consent. * inability to tolerate imaging procedure (i.e., remain relatively still for multiple short durations of 3-4 minutes) over a total time of 20 minutes.

Keywords: moh's surgery mosaicing algorithm intraoperative imaging 12-239
comparison of two- versus three-antibiotic therapy for pulmonary mycobacterium avium complex disease

Conditions: Mycobacterium Avium Complex; Nontuberculous Mycobacterium Infection

Summary: ntm therapy consists of a multi-drug macrolide based regimen for 18-24 months. treated patients frequently experience debilitating side effects, and many patients delay the start of antibiotic treatment due to these risks. common side effects include nausea, diarrhea, and fatigue, and rare but serious toxicities include ocular toxicity, hearing loss, and hematologic toxicity. to date, most of the evidence underlying the current treatment recommendations has come from observational studies in which either a macrolide has been combined with rifampin and ethambutol, or in some cases combined with ethambutol alone. the proposed study will answer whether a third drug is necessary or whether taking two drugs can increase tolerability without a substantial loss of efficacy.

mycobacterium avium complex (mac) are a subset of nontuberculous mycobacteria (ntm), environmental bacteria that can cause chronic, debilitating pulmonary disease, primarily affecting those over age 60. the goals of treatment are to improve symptoms, stop disease progression, and clear the infection. we propose to address a longstanding controversy in the therapy of pulmonary mac disease, whether patients must take three antibiotics concomitantly, or if two are sufficient. the study is a multicenter randomized pragmatic clinical trial to compare azithromycin + ethambutol (2-drug therapy) vs. azithromycin + ethambutol + rifampin (3-drug therapy) for non-cavitary pulmonary mac disease. all clinical outcomes will be considered standard of care and abstracted from clinical records. therapy changes and adverse events will be recorded at routine visits. health-related quality of life (hrqol) and self-reported toxicity will be captured centrally in a web-based database, and ct scans will be read centrally. co-primary outcomes are culture conversion and tolerability of treatment. the primary analysis for culture conversion will be conducted as a per-protocol non-inferiority analysis, and the primary analysis for tolerability will be conducted as an intention-to-treat superiority analysis.

Eligibility criteria:
inclusion criteria: * culture positive pulmonary mac meeting ats/idsa disease criteria * age over 18 years * ability to provide informed consent exclusion criteria: * fibrocavitary disease * planned surgery for mac disease * patients who have cumulatively taken 6 weeks or more of multi-drug antimicrobial treatment for mac * patients who are currently taking or have taken multi-drug antimicrobial treatment for ntm within the prior 30 days * diagnosis of cystic fibrosis * diagnosis of hiv * history of solid organ or hematologic transplant * significant drug-drug interaction not clinically manageable in the opinion of the investigator * contraindication to any component of the study treatment regimen

Keywords: ntm mac mycobacteria nontuberculous mycobacteria azithromycin ethambutol rifampin
effect spinal orthosis on sagittal and frontal parameters in scoliosis

Conditions: Adolescent Idiopathic Scoliosis

Summary: it has been observed that there are insufficient studies on whether the conservative treatment of ais with chêneau spinal orthosis provides 3d correction on the scoliotic curve and its effect on the spine and lower extremity parameters. the aim of this study is to investigate the effect of chêneau spinal orthosis application on sagittal and frontal parameters at 3 and 6 months follow-up in adolescent idiopathic scoliosis.

adolescent idiopathic scoliosis (ais) is a three-dimensional deformity of the spine that is commonly seen in individuals aged 10-18 years, and spinal orthosis application, one of the conservative treatment methods, is widely preferred today. lyon, milwaukee, gensingen, boston and rigo system chêneau spinal orthoses are among the most frequently preferred today. rigo system chêneau (rcs) spinal orthosis aims to correct scoliosis in 3d in sagittal, transverse and coronal planes. studies have indicated that spinal orthosis application may have limited corrective effect on sagittal and transverse planes scoliotic curvature. in order to obtain the most effective result in spinal orthosis application, it is important to fully understand the connection mechanisms between different planes and their relationship with the lower extremity. it has been observed that studies on whether conservative treatment of spinal orthosis in adolescent idiopathic scoliosis (ais) can provide 3d correction on the scoliotic curve and its effect on spine and lower extremity parameters are insufficient. ais individuals who will undergo chêneau type spinal orthosis application that meets the inclusion criteria will be included in the study. demographic information of the participants will be obtained with a patient information form and a scoliosis assessment form. radiographs are planned to be obtained using an eos (eos-imaging®, paris, france) imaging device, which is a low-dose imaging device that provides simultaneous anterior-posterior and lateral views while standing. spine and lower extremity parameters will be evaluated from the obtained images. plantar pressure and balance assessment is planned to be performed with a diers pedoscan device connected to the diers formetric system. srs-22 (scoliosis research society-22) questionnaire is planned to be used in the assessment of the quality of life of the individuals. brace questionnaire is planned to be used in the assessment of spinal orthosis satisfaction. all data will be evaluated by statistical analysis methods.

Eligibility criteria:
inclusion criteria: * 10-18 years old * cobb angle: 15-45° * individuals with ais who will be using a chêneau type spinal orthosis for the first time • spinal orthosis recommended for at least 18 hours per day * risser ≤ 3 exclusion criteria: * using a foot orthosis * neurological problem * surgery history * lower extremity length difference greater than 1 cm

Keywords: adolescent idiopathic scoliosis scoliosis brace 3d spine analysis plantar pressure
mindfulness-based prenatal education on women

Conditions: Depression, Anxiety

Summary: the purpose of this study is to explore the differences between stress, anxiety, depression, mindfulness, mother and infants bonding, salivary amylase activity, and postnatal maternal outcomes for prenatal mental disorders in women with mindfulness prenatal education program

the aim of this study was to test the efficacy of a mindfulness prenatal education program in reducing pregnant women's perceived stress, anxiety, depression, mindfulness, mother and infant bonding, and salivary alpha-amylase compared to a control group. the investigators hypothesize that using the mindfulness prenatal education program by the study group will lead to improved related mood symptoms compared with the control group. randomized controlled trial comparing two education programs with health and singleton pregnant women is run by the random allocation software (saghaei, 2004). use the g-power 3.1.9 windows: repeated measures and between factors among two groups to calculate the number of samples, and setting the power = .8, α = .05, effect size = .25. the estimated number of samples may be lost 30%, total 102 samples.

Eligibility criteria:
inclusion criteria: * subjects were at the age over 20 * could speak and read chinese fluently * willing and be ale to attend the education program exclusion criteria: * taking medication for diagnosing mental illness * with complicated or high-risk pregnancies
developing a program for transition to adult care for youth with chronic conditions : a mixed method study

Conditions: Transition Care

Summary: investigation in 3 steps the transition of young people with chronic diseases. first step: qualitative survey. interviews with carers, young people and parents. chronic diseases studied: epilepsy, hiv, sickle cell disease, obesity. second step: delphi consensus survey. vote on internet : carers, patients' associations, young people and family. chronic diseases studied: all. third step: validation survey. vote on internet : young people. chronic diseases studied: all.


Eligibility criteria:
inclusion criteria: * youth with chronic diseases after transfer to adult care * parents or guardians of these youth. * professionals caregivers from pediatric services and adult services involved in transition exclusion criteria: -